Mylan II B.V.
Healthcare · Pharmaceutical Preparations · P7 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $11.37B | $11.27B | $11.76B | $10.97B | $9.43B | $7.72B |
| Operating income | $715.5M | $905.6M | $1.44B | $699.2M | $1.46B | $1.35B |
| Net income | $16.8M | $352.5M | $696.0M | $480.0M | $847.7M | $933.1M |
| Total assets | $31.26B | $32.73B | $35.81B | $34.73B | $22.27B | $15.82B |
| Total liabilities | $19.37B | $20.57B | $22.50B | $23.61B | $12.50B | $12.54B |
| Equity | $11.88B | $12.17B | $13.31B | $11.12B | $9.77B | $3.28B |
| EPS (diluted) | $0.03 | $0.68 | $1.30 | $0.92 | $1.70 | $2.34 |
| Shares out. | 515.9M | 514.8M | 535.5M | 490.7M | 497.4M | 398.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- 6.3%
- Net margin
- 0.1%
- Return on equity
- 0.1%
- Return on assets
- 0.1%
- Return on capital (ROCE)
- 2.8%
- Liabilities / assets
- 62.0%
- Debt / equity
- 1.63×
- Book value / share
- $23.03
- Revenue growth (YoY)
- 0.9%
- Net income growth (YoY)
- −95.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- 1.68grey zone
- Accruals / assets
- −5.7%clean
- Beneish M-Score
- -2.69normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 4 good- Altman Z″ in the grey zone
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Bresch Heather MOfficer — Chief Executive Officer | Nov 16, 2020 | D | 580,642 | — |
| Parrish Mark WDirector | Nov 16, 2020 | D | 58,295 | — |
| Coury Robert JOfficer — Executive Chairman | Nov 16, 2020 | D | 1.4M | — |
| Cindrich Robert JDirector | Nov 16, 2020 | Option exercise | 9,440 | $0.00 |
| Lyons Dillon JoellenDirector | Nov 16, 2020 | D | 15,609 | — |
| Dimick Neil FDirector | Nov 16, 2020 | D | 51,263 | — |
| Mauro AnthonyOfficer — Chief Commercial Officer | Nov 16, 2020 | D | 119,305 | — |
| Higgins Melina EDirector | Nov 16, 2020 | D | 39,131 | — |
| Malik RajivOfficer — President | Nov 16, 2020 | D | 459,699 | — |
| Vanderveen Randall LDirector | Nov 16, 2020 | Option exercise | 9,440 | $0.00 |
| Korman HarryDirector | Nov 16, 2020 | D | 26,515 | — |
| Mark Richard ADirector | Nov 16, 2020 | D | 9,228 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · New financial obligation · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer changeNov 19, 2020
- Results of operationsNov 6, 2020
- Entered a material agreementSep 11, 2020
- Results of operations · Other material eventAug 6, 2020
- Shareholder voteJul 2, 2020
- Other material eventJun 19, 2020
- Entered a material agreementJun 17, 2020
- Other material eventJun 12, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- S-3ASRMay 8, 2025
- S-3ASRMay 6, 2022
- EFFECTSep 28, 2021
- 424B3Sep 28, 2021
- UPLOADSep 17, 2021
- S-4FORM S-4Sep 10, 2021
- 15-15DNov 27, 2020
- 8-KNov 19, 2020
- 4FORM 4 SUBMISSIONNov 18, 2020
- 4FORM 4 SUBMISSIONNov 18, 2020
- 4FORM 4 SUBMISSIONNov 18, 2020
- 4FORM 4 SUBMISSIONNov 18, 2020
- 4FORM 4 SUBMISSIONNov 18, 2020
- 4FORM 4 SUBMISSIONNov 18, 2020
- 4FORM 4 SUBMISSIONNov 18, 2020
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.